STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2734 by analyst upside · 2026-06-27
ARWR
Arrowhead Pharmaceuticals, Inc.
Healthcare · Market Cap $11B · P/E 0x
ANALYST PRICE TARGET
+12.9%
implied upside to consensus target
Current Price $78.89
Consensus Target $89.08
Bull Target $110.0
Bear Target $46.0
Analysts Covering 12
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
7
Hold
3
Sell
0
52-Week Low $14.3
52-Week High $84.55
YTD Return +16.4%
FUNDAMENTALS
Market Cap $11B
P/E Ratio (TTM) N/A
Forward P/E -18.2x
EPS (TTM) $-2.27
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $622M
Profit Margin -48.4%
52-WEEK RANGE
52-Week Low $14.3
52-Week High $84.55
Current Price $78.89
Bear Target $46.0
Bull Target $110.0
● Now $78.89 ● Target $89.08
TRADING DATA
Avg Volume 1.7M
YTD Return +16.4%
Analyst Count 12
Consensus Buy
Upside to Target +12.9%
Last Updated 2026-06-27

ANALYST SUMMARY

Arrowhead Pharmaceuticals, Inc. (ARWR) is currently trading at $78.89 with a Wall Street consensus price target of $89.08, implying potential upside of 12.9% over the next 12 months. 12 analysts currently cover ARWR, with a consensus rating of Buy - 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $110.0, while the most cautious has a target of $46.0.

ARWR operates in the Healthcare sector with a market capitalisation of $11B. The stock is up 16.4% year-to-date and is currently trading near the upper end of its 52-week range of $14.3 – $84.55.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ARWR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Leerink Partners — Reiterated
Market Perform → Market Perform 2026-06-17 29% win rate (7 calls)
Bernstein — Reiterated
Market Perform → Market Perform 2026-05-13 Building track record
RBC Capital — Reiterated
Outperform → Outperform 2026-05-08 Building track record
JP Morgan ● Initiated
Overweight 2026-05-01 43% win rate (7 calls)
Morgan Stanley ↑ Upgrade
Equal-Weight → Overweight 2026-04-21 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-03-25 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-02-10 31% win rate (48 calls)
B. Riley Securities — Reiterated
Buy → Buy 2026-01-22 17% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
48
out of 100
Coverage depth
20/30
Consensus clarity
14/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →